Differential Effects of Genetically Determined Cholesterol Efflux Capacity on Coronary Artery Disease and Ischemic Stroke

被引:0
|
作者
Jin, Aoming [1 ,2 ]
Wang, Mengxing [1 ,2 ]
Chen, Weiqi [1 ,2 ]
Yan, Hongyi [1 ,2 ]
Xiang, Xianglong [1 ,2 ]
Pan, Yuesong [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
cholesterol efflux capacity; Mendelian randomization; coronary artery disease; stroke; genetics; HIGH-DENSITY-LIPOPROTEIN; MENDELIAN RANDOMIZATION; CARDIOVASCULAR RISK; HDL CHOLESTEROL; EVENTS; ASSOCIATION; INSTRUMENTS; METAANALYSIS; BIAS;
D O I
10.3389/fcvm.2022.891148
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundObservational studies indicated that cholesterol efflux capacity (CEC) of high-density lipoprotein (HDL) is inversely associated with cardiovascular events, independently of the HDL cholesterol concentration. The aim of the study is to examine the casual relevance of CEC for coronary artery disease (CAD) and myocardial infarction (MI), and compare it with that for ischemic stroke and its subtypes using a Mendelian randomization approach. MethodsWe performed a 2-sample Mendelian randomization to estimate the casual relationship of CEC with the risk of CAD, MI, and ischemic stroke. A CEC-related genetic variant (rs141622900) and other five genetic variants were used as the instrumental variables. Association of genetic variants with CAD were estimated in a GWAS involving 60,801 CAD cases and 123,504 controls. They were then compared with the associations of these variants with ischemic stroke and its subtypes (large vessel, small vessel, and cardioembolic) involving 40,585 ischemic stroke cases and 406,111 controls. ResultsUsing the SNP of rs141622900 as the instrument, a 1-SD increase in CEC was associated with 45% lower risk for CAD (odds ratio [OR] 0.55, 95% confidence interval [CI] 0.44-0.69, p < 0.001) and 33% lower risk for MI (odds ratio [OR] 0.67, 95% CI 0.52-0.87, p = 0.002). By contrast, the causal effect of CEC was much weaker for ischemic stroke (odds ratio [OR] 0.79, 95% CI 0.64-0.97, p = 0.02; p for heterogeneity = 0.03) and, in particular, for cardioembolic stroke (p for heterogeneity = 0.006) when compared with that for CAD. Results using five genetic variants as the instrument also indicated consistently weaker effects on ischemic stroke than on CAD. ConclusionGenetic predicted higher CEC may be associated with decreased risk of CAD. However, the casual association of CEC with ischemic stroke and specific subtypes would need to be validated in further Mendelian randomization studies.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Cholesterol efflux capacity in coronary artery disease: a meta-analysis
    Ye, Huiming
    Xu, Guiyu
    Ren, Lihui
    Peng, Jianjun
    CORONARY ARTERY DISEASE, 2020, 31 (07) : 642 - 649
  • [2] Genetically determined intelligence and coronary artery disease risk
    Li, Ling
    Pang, Shichao
    Zeng, Lingyao
    Gueldener, Ulrich
    Schunkert, Heribert
    CLINICAL RESEARCH IN CARDIOLOGY, 2021, 110 (02) : 211 - 219
  • [3] Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease
    Norimatsu, Kenji
    Kuwano, Takashi
    Miura, Shin-ichiro
    Shimizu, Tomohiko
    Shiga, Yuhei
    Suematsu, Yasunori
    Miyase, Yuiko
    Adachi, Sen
    Nakamura, Ayumi
    Imaizumi, Satoshi
    Iwata, Atsushi
    Nishikawa, Hiroaki
    Uehara, Yoshinari
    Saku, Keijiro
    HEART AND VESSELS, 2017, 32 (01) : 30 - 38
  • [4] High-density lipoprotein cholesterol efflux capacity and incidence of coronary artery disease and cardiovascular mortality: a systematic review and meta-analysis
    Cheng, Wenke
    Rosolowski, Maciej
    Boettner, Julia
    Desch, Steffen
    Jobs, Alexander
    Thiele, Holger
    Buettner, Petra
    LIPIDS IN HEALTH AND DISEASE, 2022, 21 (01)
  • [5] Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease
    Kenji Norimatsu
    Takashi Kuwano
    Shin-ichiro Miura
    Tomohiko Shimizu
    Yuhei Shiga
    Yasunori Suematsu
    Yuiko Miyase
    Sen Adachi
    Ayumi Nakamura
    Satoshi Imaizumi
    Atsushi Iwata
    Hiroaki Nishikawa
    Yoshinari Uehara
    Keijiro Saku
    Heart and Vessels, 2017, 32 : 30 - 38
  • [6] Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study
    Liu, Chaoqun
    Zhang, Yuan
    Ding, Ding
    Li, Xinrui
    Yang, Yunou
    Li, Qing
    Zheng, Yuanzhu
    Wang, Dongliang
    Ling, Wenhua
    ATHEROSCLEROSIS, 2016, 249 : 116 - 124
  • [7] Prognostic Usefulness of Serum Cholesterol Efflux Capacity in Patients With Coronary Artery Disease
    Zhang, Jianhua
    Xu, Jia
    Wang, Jingfeng
    Wu, Changhao
    Xu, Yan
    Wang, Yueguo
    Deng, Fengfeng
    Wang, Zhe
    Chen, Xuhua
    Wu, Mengzuo
    Chen, Yangxin
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (04) : 508 - 514
  • [8] Associations of Observational and Genetically Determined Caffeine Intake With Coronary Artery Disease and Diabetes Mellitus
    Said, M. Abdullah
    van de Vegte, Yordi J.
    Verweij, Niek
    van der Harst, Pim
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (24):
  • [9] Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke
    Marchis, Gian Marco De
    Dittrich, Tolga D.
    Malik, Rainer
    V. Zietz, Annaelle
    Kriemler, Lilian F.
    Ference, Brian A.
    Dichgans, Martin
    Georgakis, Marios K.
    ATHEROSCLEROSIS, 2022, 361 : 41 - 46
  • [10] Genetically Determined Height and Coronary Artery Disease
    Nelson, C. P.
    Hamby, S. E.
    Saleheen, D.
    Hopewell, J. C.
    Zeng, L.
    Assimes, T. L.
    Kanoni, S.
    Willenborg, C.
    Burgess, S.
    Amouyel, P.
    Anand, S.
    Blankenberg, S.
    Boehm, B. O.
    Clarke, R. J.
    Collins, R.
    Dedoussis, G.
    Farrall, M.
    Franks, P. W.
    Groop, L.
    Hall, A. S.
    Hamsten, A.
    Hengstenberg, C.
    Hovingh, G. Kees
    Ingelsson, E.
    Kathiresan, S.
    Kee, F.
    Koenig, I. R.
    Kooner, J.
    Lehtimaeki, T.
    Maerz, W.
    McPherson, R.
    Metspalu, A.
    Nieminen, M. S.
    O'Donnell, C. J.
    Palmer, C. N. A.
    Peters, A.
    Perola, M.
    Reilly, M. P.
    Ripatti, S.
    Roberts, R.
    Salomaa, V.
    Shah, S. H.
    Schreiber, S.
    Siegbahn, A.
    Thorsteinsdottir, U.
    Veronesi, G.
    Wareham, N.
    Willer, C. J.
    Zalloua, P. A.
    Erdmann, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (17) : 1608 - 1618